MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas

Ovarian cancer is a silent disease with a poor prognosis that urgently requires new therapeutic strategies. In low-grade ovarian tumours, mutations in the MAP3K BRAF gene constitutively activate the downstream kinase MEK. Here we demonstrate that an additional MAP3K, MAP3K8 (TPL-2/COT), accumulates...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Nat Commun
Auteurs principaux: Gruosso, Tina, Garnier, Camille, Abelanet, Sophie, Kieffer, Yann, Lemesre, Vincent, Bellanger, Dorine, Bieche, Ivan, Marangoni, Elisabetta, Sastre-Garau, Xavier, Mieulet, Virginie, Mechta-Grigoriou, Fatima
Format: Artigo
Langue:Inglês
Publié: Nature Pub. Group 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4633961/
https://ncbi.nlm.nih.gov/pubmed/26456302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms9583
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires